Download the AUA Guidelines-At-A-Glance mobile app:
|Clinically Localized Prostate Cancer||Muscle Invasive Bladder Cancer|
|Renal Mass||Stress Urinary Incontinence (SUI)|
AUA Seeking Review and Comments on the New Draft of Guideline on Testosterone Replacement Therapy Guideline
The AUA is providing members and other interested parties the opportunity to review and provide comments on the draft guideline on Testosterone Replacement Therapy. The draft guideline will be available for review in the next month, and a time period of approximately two weeks will be allotted for this assessment. Before being sent a copy of the draft guideline, all reviewers must disclose their current industry relationships on the AUA website in order to comply with the AUA's conflict of interest (COI) policy and sign a non-disclosure agreement (NDA) to be provided. Information about the draft must be kept confidential until after the guideline has been published to the AUA website in its final state.
Interested reviewers, both AUA members and non-members, should email their name, address, AUA ID # and email address to LRahimi@auanet.org. Non-members will receive an AUA ID # so they may also disclose their industry relationships on the AUA website and submit a signed copy of the non-disclosure agreement.
The deadline to request the guideline is August 21, 2017 in order to qualify to review and receive the draft guideline. Requests after that date cannot be processed.